Monograph Title | Section | Source Publication Sort descending | Page Number | Errata Post Date | Errata Official Date | Target Errata Print Publication | Target Online Fix Publication | Description |
---|---|---|---|---|---|---|---|---|
CALCIUM SULFATE | ASSAY/Procedure | USP35–NF30 | 1724 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 5 of Titrimetric system: Delete the subsection Blank: 100 mL of water and 4 mL of 3 N hydrochloric acid AND Line 11 of Analysis: Delete the sentence Perform a blank determination. AND Line 13 of Analysis: Change Result = [(V − B… Read More |
MICROCRYSTALLINE CELLULOSE | IDENTIFICATION/B. Procedure | USP35–NF30 | 1746 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | 4th formula of Analysis: Change
Result = (95) × [η]c/WS × [(100 − %LOD)/100] to: Result = [(95) × [η]c]/{WS × [(100 − %LOD)/100]} |
MAGNESIUM STEARATE | IMPURITIES/Chloride and Sulfate, Sulfate <221> | USP35–NF30 | 1847 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 3: Change
0.020 N sulfuric acid (1.0%) to: 0.020 M sulfuric acid (1.0%) |
METHYL ALCOHOL | ASSAY/Procedure | USP35–NF30 | 1865 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 9 of System suitability: Change
Tailing factor: NLT 1.5 for methyl alcohol, System suitability solution to: Tailing factor: NMT 1.5 for methyl alcohol, System suitability solution |
POLYETHYLENE OXIDE | IMPURITIES/Organic Impurities/Procedure: Limit of Free Ethylene Oxide | USP35–NF30 | 1906 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 2 of System suitability: Change
Samples: Standard stock solution and Standard solution C to: Sample: Standard solution C |
<621> CHROMATOGRAPHY | SYSTEM SUITABILITY/Stationary Phase | USP35–NF30 | 258 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 3 of Flow Rate (HPLC): Change … Read More |
POLYSORBATE 20 | SPECIFIC TESTS/Acid Value | USP35–NF30 | 1919 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 1 of Sample: Change
10.0 to: 10.0 g |
<1050> VIRAL SAFETY EVALUATION OF BIOTECHNOLOGY PRODUCTS DERIVED FROM CELL LINES OF HUMAN OR ANIMAL ORIGIN | VI. Evaluation and Characterization of Viral Clearance Procedures | USP35–NF30 | 553 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Row 10 (Reovirus 3) of Column 5 (Genome) of Table A-1: Change DNA to: RNA |
POLYSORBATE 60 | SPECIFIC TESTS/Acid Value | USP35–NF30 | 1920 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 1 of Sample: Change
10.0 to: 10.0 g |
ACESULFAME POTASSIUM | IMPURITIES/Limit of Fluoride | USP35–NF30 | 1680 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 25 of Analysis: Change C = concentration of fluoride in the Sample solution, from the standard curve (mg/mL) to: C = concentration of fluoride in the Sample solution, from the standard curve (µg/mL) |
SODIUM HYDROXIDE | ASSAY/Procedure | USP35–NF30 | 1955 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 10 of Analysis: Change
Result = {[(VS1 − VB) × N × F1]/W} × 100 to: Result = {[(VS2 − VB) × N × F1]/W} × 100 AND Line 11 of … Read More |
CALCIUM SULFATE | SPECIFIC TESTS/Loss on Drying <731> | USP35–NF30 | 1724 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Acceptance criteria: Change NMT 1.5% for the anhydrous form and NMT 19.0%–23.0% for the dihydrate to: NMT 1.5% for the anhydrous form and 19.0%–23.0% for the dihydrate |
<81> Antibiotics—Microbial Assays | Turbidimetric Method | USP35–NF30 | 74 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 8 of Analysis: Change Include in each rack 1–2 control tubes containing 1 mL of the inoculum medium (see Table 8) but no antibiotic. to: Include in each rack 1–2 control tubes containing 1 mL of the test diluent (see Table 7) but no antibiotic. |
GLYCERYL BEHENATE | IMPURITIES | USP35–NF30 | 1811 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 34 of Content of 1-Monoglycerides/Analysis: Change F = equivalency factor of glyceryl monobehenate, 207.3 mg/mEq to: F = equivalency factor of glyceryl monobehenate, 0.2073 g/mEq AND Line 19 of Limit of Free Glycerin/Analysis: Change … Read More |
TREHALOSE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP35–NF30 | 2007 | 28-Sep-2012 | 1-Oct-2012 | USP37–NF32 | First Supplement to USP36–NF31 | Line 2: Delete
USP Glycerin RS |
IFOSFAMIDE | Chloroform-insoluble phosphorus | USP35–NF30 | 3477 | 29-Mar-2013 | 1-Apr-2013 | USP37–NF32 | USP37–NF32 | Line 18 of Test preparation: Change ammonium hydroxide solution. to: ammonium hydroxide. |
Polysorbate 80 | SPECIFIC TESTS/Fats and Fixed Oils, Hydroxyl Value <401> | USP35–NF30 | 1920 | 30-Nov-2012 | 1-Dec-2012 | USP37–NF32 | Second Supplement to USP36–NF31 | Line 13 of Analysis: Change 0.5 N alcoholic potassium hydroxide to: 0.5 N alcoholic potassium hydroxide VS |
GLYCERYL MONOOLEATE | SPECIFIC TESTS/Fats and Fixed Oils, Fatty Acid Composition <401> | USP35–NF30 | 1814 | 31-Jan-2013 | 1-Feb-2013 | USP37–NF32 | Second Supplement to USP36–NF31 | Column 3 of Table 1: Change in Row 1 Percentage, NMT (%) to: Percentage (%) Change in Row 2 12.0 to: NMT 12.0 Change in Row 3 6.0 to: NMT 6.0 Change in Row 4 60.0 to: NLT 60.0 Change in Row 5 35.0 to: NMT 35.0 Change in Row 6 2.… Read More |
THIMEROSAL TOPICAL AEROSOL | SPECIFIC TESTS/Alcohol Determination, Method II <611> | USP36–NF31 | 5369 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 4 of Analysis: Change Determine the alcohol content of the sample thus prepared by the Gas–Liquid Chromatographic Method (see Method II in Alcohol Determination <611>, using methyl ethyl ketone as the internal standard in place of acetone. to: … Read More |
ONDANSETRON ORAL SOLUTION | Related compounds | USP36–NF31 | 4586 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36/329.82)10,000(1 / F)(1 / V)(CS / CA)(ri / rS) to: (293.36 / 329.83)10,000(1 / F)(1 / V)(CS / CA)(ri… Read More |
OLMESARTAN MEDOXOMIL | IMPURITIES/Organic Impurities/Impurity Table | USP36–NF31 | 4570 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote d: Change ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(1-trityl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylate. to: (5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-((2´-(2-trityl-1… Read More |
POTASSIUM METAPHOSPHATE | SPECIFIC TESTS/Viscosity—Capillary Viscometer Methods <911> and Rotational Rheometer Methods <912> | USP36–NF31 | 2172 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1: Change and to: or |
TROLAMINE SALICYLATE | Assay | USP36–NF31 | 5499 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Chromatographic system: Change L1 to: L7 |
ONDANSETRON ORAL SOLUTION | Assay | USP36–NF31 | 4586 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 7 of Procedure: Change (293.36/329.82)100(C/V)(rU / rS) to: (293.36 / 329.83)100(C / V)(rU / rS) AND Line 8 of Procedure: Change 329.82 to: 329.83 |
TRAMADOL HYDROCHLORIDE EXTENDED-RELEASE TABLETS | IMPURITIES/Organic Impurities/Table 2 | USP36–NF31 | 5438 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Footnote c: Change 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-1-ene hydrochloride (identified and reported as an individual unspecified impurity if present). to: 1-(3-Methoxyphenyl)-2-(dimethylaminomethyl) cyclohex-6-ene hydrochloride (identified and reported as an individual… Read More |
SORBITAN MONOLAURATE | IDENTIFICATION/A. | USP36–NF31 | 2212 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 260–280 to: 260–280 on 1-g sample |
<228> ETHYLENE OXIDE AND DIOXANE | Method II | USP36–NF31 | 148 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 31 of Analysis: Change rS = ethylene oxide peak responses from Standard solution B to: rS = dioxane peak responses from Standard solution B |
VERAPAMIL HYDROCHLORIDE ORAL SOLUTION | Assay | USP36–NF31 | 5558 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3 of Sodium acetate solution: Change 0.01 M to: 0.01 N AND Line 6 of Assay preparation: Change 10-mL to: 100-mL |
SODIUM ACETATE | IMPURITIES/Inorganic Impurities/Potassium | USP36–NF31 | 5147 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 1 of Sample solution: Change Equivalent to 600 mg/mL of anhydrous sodium acetate to: Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water. AND Line 1 of Analysis: Change To 5 mL of Sample solution add to: To the Sample… Read More |
VENLAFAXINE HYDROCHLORIDE | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5551 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2… Read More |
SORBITAN MONOOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2213 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS | METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES | USP36–NF31 | 619 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Change the section title Method 6—Postcolumn DABS-CI Derivatization General Principle to: Method 6—Precolumn DABS-CI Derivatization General Principle |
THALIDOMIDE CAPSULES | Dissolution <711> | USP36–NF31 | 5347 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | After the Test solution section: Add to: Chromatographic system—Prepare as directed in the Assay under Thalidomide. |
VENLAFAXINE TABLETS | ADDITIONAL REQUIREMENTS/USP Reference Standards <11> | USP36–NF31 | 5554 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 2 of Venlafaxine Related Compound A RS: Change 1-(1-(4-methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol. C16H25NO2 263.38 to: 1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride. C16H25NO2… Read More |
SORBITAN MONOPALMITATE | IDENTIFICATION/A. | USP36–NF31 | 2213 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 210–225 to: 210–225 on 1-g sample |
<1052> BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS | APPENDIX | USP36–NF31 | 619 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Change the section title Method 6—Postcolumn DABS-CI Derivatization to: Method 6—Precolumn DABS-CI Derivatization |
THIMEROSAL | IMPURITIES/Mercury Ions | USP36–NF31 | 5368 | 28-Mar-2014 | 1-Apr-2014 | USP38–NF33 | USP38–NF33 | Line 19 of Analysis: CS = concentration of mercuric chloride in the Standard solution (mg/mL) to: CS = concentration of mercuric chloride in Sample solution B (mg/mL) |
VERAPAMIL HYDROCHLORIDE ORAL SUSPENSION | Assay | USP36–NF31 | 5558 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 2 of Mobile phase: Change 0.01 M to: 0.01 N AND Line 7 of Assay preparation: Change 10-mL to: 100-mL |
SORBITAN MONOSTEARATE | IDENTIFICATION/A. | USP36–NF31 | 2214 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 200–215 to: 200–215 on 1-g sample |
CARAWAY OIL | DEFINITION | USP36–NF31 | 1924 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 3: Change It contains NMT 50.0% of d-carvone (C10H14O). to: It contains NLT 50.0% of d-carvone (C10H14O). |
GLYCERYL TRISTEARATE | IDENTIFICATION/Fatty Acid Composition | USP36–NF31 | 2033 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 19 of Analysis: Change Result = [(FMC × PFA1 × AMC)/(PMC × AFA1)] × 100 to: Result = (FMC × PFA1 ×… Read More |
VITAMIN E | SPECIFIC TESTS/Acidity | USP36–NF31 | 5579 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sample: Change 40 mg to: 1.0 g |
SORBITAN SESQUIOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2215 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
NITRIC ACID | ASSAY/Procedure | USP36–NF31 | 2107 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1 of Sample solution: Change To 2 mL of Nitric Acid in a tared, glass-stoppered conical flask add 25 mL of water. to: Weigh 2 mL of Nitric Acid in a glass-stoppered conical flask, and add 25 mL of water. |
ANAGRELIDE HYDROCHLORIDE | ASSAY/Procedure/Chromatographic system/System suitability | USP36–NF31 | 2500 | 31-Jan-2014 | 1-Feb-2014 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 2 of Suitability requirements: Change Column efficiency: NMT to: Column efficiency: NLT |
SORBITAN TRIOLEATE | IDENTIFICATION/A. | USP36–NF31 | 2216 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Sample: Change 1 g of the residue of oleic acid obtained in the Assay for Fatty Acids to: Residue obtained in the Assay for Fatty Acids AND Line 2 of Acceptance criteria: Change 192–204 to: 192–204 on 1-g sample |
STINGING NETTLE | COMPOSITION/Content of Total Amino Acids | USP36–NF31 | 1604 | 26-Jul-2013 | 1-Aug-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 1 of Reagent solution: Change Solution containing 1.00 g of ninhydrin, 1.50 g of hydrindantin, to: Solution containing 1.00 g of ninhydrin, 150 mg of hydrindantin, |
STEAROYL POLYOXYLGLYCERIDES | IMPURITIES/Limit of Free Glycerol | USP36–NF31 | 2250 | 27-Sep-2013 | 1-Oct-2013 | USP38–NF33 | First Supplement to USP37–NF32 | Line 11 of Analysis: Change (VS − VB) to: (VB − VS) AND Line 12 of Analysis: Change VS = Titrant volume consumed by the Sample… Read More |
BOSWELLIA SERRATA | COMPOSITION/Content of Keto-Derivatives of β-Boswellic Acids/System suitability/Suitability requirements | USP36–NF31 | 1366 | 22-Nov-2013 | 1-Dec-2013 | USP38–NF33 | Second Supplement to USP37–NF32 | Line 1 of Tailing factor: Change 11-keto-β-boswellic acid peak to: 3-acetyl-11-keto-β-boswellic acid peak |
ALBUTEROL SULFATE | Chromatographic purity | USP36–NF31 | 2352 | 31-May-2013 | 1-Jun-2013 | USP37–NF32 | USP37–NF32 | Line 1: Change It meets the requirements of the test for Chromatographic purity under Albuterol, except to read Albuterol Sulfate in place of Albuterol and to use water instead of methanol as the solvent to prepare the Standard solution and the Test solution. to… Read More |